Continuing to recognize the value of digital platforms in healthcare provision during the COVID-19 era, the United States Drug Enforcement Administration (DEA) and Department of Health and Human Services (HHS) have issued a temporary rule to extend flexibilities for the prescription of controlled substances via telemedicine.
A detailed statement from the law firm Arnall Golden Gregory LLP outlines that the DEA and HHS action goes further to extend the full set of telemedicine flexibilities in relation to prescription of controlled medications that were provisioned during the COVID–19 Public Health Emergency (COVID–19 PHE). The rule will stay effective through December 31, 2024.
The DEA’s move marks the second extension of its telemedicine allowance, a sign of the increasing significance of telemedicine within the healthcare sector. The enforcement flexibilities were initially established to aid healthcare providers to continue offering services during the pandemic, while minimizing risk to patients and providers alike.
These continuous allowances provide healthcare providers the capability to prescribe controlled substances via telemedicine without a prior in-person examination. By granting this extension, the DEA shows recognition of the ongoing impact of the pandemic and the importance of providing adequate and safe healthcare access while maintaining the control over misuse of substances.
It’s a point of note for legal professionals working in healthcare and pharmaceutical sectors. The implication of these measures, in terms of addressing regulatory compliance while concurrently ensuring patient safety and accessibility to medically necessary treatments, reveals an arena where law and health policy intersects. It also offers food for thought about the future shape of pharmaceutical law and telemedicine in a post-COVID world.